Dextroamphetamine has 33 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 15 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Furazolidone, Mao Inhibitors, Buspirone. Patients taking Dextroamphetamine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 33
- Contraindicated
- 2
- Major
- 15
- Moderate
- 11
Contraindicated (2)
- Dextroamphetamine + Furazolidone— A metabolite of furazolidone slows amphetamine metabolism, causing hypertensive crisis and potentially fatal neurologica…
- Dextroamphetamine + Mao Inhibitors— MAOIs slow amphetamine metabolism, increasing norepinephrine release and causing hypertensive crisis, toxic neurological…
Major (15)
- Dextroamphetamine + Buspirone— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and discontinue if serotonin syndrome occurs.
- Dextroamphetamine + Desipramine— Amphetamines enhance activity of desipramine causing striking and sustained effects.
- Dextroamphetamine + Fentanyl— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and discontinue if serotonin syndrome occurs.
- Dextroamphetamine + Fluoxetine— CYP2D6 inhibitor and serotonergic drug; increases dextroamphetamine exposure and serotonin syndrome risk. Use lower dose…
- Dextroamphetamine + Lithium— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and discontinue if serotonin syndrome occurs.
- Dextroamphetamine + Lovastatin— While there are no adequate and well-controlled studies in pregnant women, there has been one report of severe congenita…
- Dextroamphetamine + Paroxetine— CYP2D6 inhibitor and serotonergic drug; increases dextroamphetamine exposure and serotonin syndrome risk. Use lower dose…
- Dextroamphetamine + Protriptyline— Amphetamines enhance activity of protriptyline causing striking and sustained effects.
- Dextroamphetamine + Quinidine— CYP2D6 inhibitor increases dextroamphetamine exposure and serotonin syndrome risk. Use lower doses and monitor.
- Dextroamphetamine + Ritonavir— CYP2D6 inhibitor increases dextroamphetamine exposure and serotonin syndrome risk. Use lower doses and monitor.
- Dextroamphetamine + Selective Serotonin Reuptake Inhibitors (Ssri)— Concomitant use increases risk of serotonin syndrome. Use with lower doses and monitor for serotonin syndrome symptoms.
- Dextroamphetamine + St. John'S Wort— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and discontinue if serotonin syndrome occurs.
- Dextroamphetamine + Tramadol— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and discontinue if serotonin syndrome occurs.
- Dextroamphetamine + Triptans— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and discontinue if serotonin syndrome occurs.
- Dextroamphetamine + Tryptophan— Concomitant use increases risk of serotonin syndrome. Monitor for symptoms and discontinue if serotonin syndrome occurs.
Moderate (11)
- Dextroamphetamine + Acetazolamide— Urinary alkalinizing agent increases non-ionized amphetamine concentration and decreases urinary excretion, potentiating…
- Dextroamphetamine + Acidifying Agents— Urinary acidifying agents lower blood levels and efficacy of amphetamines. Dose adjustment may be necessary.
- Dextroamphetamine + Alkalinizing Agents— Urinary alkalinizing agents increase blood levels and potentiate amphetamine action. Co-administration should be avoided…
- Dextroamphetamine + Ammonium Chloride— Urinary acidifying agent increases amphetamine ionization and urinary excretion, lowering blood levels and efficacy.
- Dextroamphetamine + Ascorbic Acid— Gastrointestinal acidifying agent lowers amphetamine absorption and blood levels, reducing efficacy.
- Dextroamphetamine + Glutamic Acid Hcl— Gastrointestinal acidifying agent lowers amphetamine absorption and blood levels, reducing efficacy.
- Dextroamphetamine + Guanethidine— Gastrointestinal acidifying agent lowers amphetamine absorption and blood levels, reducing efficacy.
- Dextroamphetamine + Reserpine— Gastrointestinal acidifying agent lowers amphetamine absorption and blood levels, reducing efficacy.
- Dextroamphetamine + Sodium Acid Phosphate— Urinary acidifying agent increases amphetamine ionization and urinary excretion, lowering blood levels and efficacy.
- Dextroamphetamine + Sodium Bicarbonate— Gastrointestinal alkalinizing agent increases amphetamine absorption, raising blood levels and potentiating actions.
- Dextroamphetamine + Thiazides— Some thiazides act as urinary alkalinizing agents, increasing amphetamine levels and potentiating effects.